JP7638955B2 - 抗ヒトｐ４０タンパク質ドメイン抗体及びその使用 - Google Patents

抗ヒトｐ４０タンパク質ドメイン抗体及びその使用 Download PDF

Info

Publication number
JP7638955B2
JP7638955B2 JP2022505553A JP2022505553A JP7638955B2 JP 7638955 B2 JP7638955 B2 JP 7638955B2 JP 2022505553 A JP2022505553 A JP 2022505553A JP 2022505553 A JP2022505553 A JP 2022505553A JP 7638955 B2 JP7638955 B2 JP 7638955B2
Authority
JP
Japan
Prior art keywords
antibody
seq
set forth
antigen
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022505553A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544050A5 (https=
JP2022544050A (ja
Inventor
シア，ユ
ワン，ジョンミン・マクスウェル
ジャン，ペン
リ，バイヨン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akeso Pharmaceuticals Inc
Original Assignee
Akeso Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akeso Biopharma Inc filed Critical Akeso Biopharma Inc
Publication of JP2022544050A publication Critical patent/JP2022544050A/ja
Publication of JP2022544050A5 publication Critical patent/JP2022544050A5/ja
Priority to JP2025024929A priority Critical patent/JP2025081517A/ja
Application granted granted Critical
Publication of JP7638955B2 publication Critical patent/JP7638955B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5434—IL-12
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022505553A 2019-07-30 2020-07-28 抗ヒトｐ４０タンパク質ドメイン抗体及びその使用 Active JP7638955B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025024929A JP2025081517A (ja) 2019-07-30 2025-02-19 抗ヒトｐ４０タンパク質ドメイン抗体及びその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN201910706137.1 2019-07-30
CN201910706137 2019-07-30
CN201911040745 2019-10-29
CN201911040745.X 2019-10-29
CN201911171754.2 2019-11-25
CN201911171754 2019-11-25
PCT/CN2020/105039 WO2021018114A1 (zh) 2019-07-30 2020-07-28 抗人p40蛋白域抗体及其用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025024929A Division JP2025081517A (ja) 2019-07-30 2025-02-19 抗ヒトｐ４０タンパク質ドメイン抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2022544050A JP2022544050A (ja) 2022-10-17
JP2022544050A5 JP2022544050A5 (https=) 2023-08-08
JP7638955B2 true JP7638955B2 (ja) 2025-03-04

Family

ID=73735954

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022505553A Active JP7638955B2 (ja) 2019-07-30 2020-07-28 抗ヒトｐ４０タンパク質ドメイン抗体及びその使用
JP2025024929A Pending JP2025081517A (ja) 2019-07-30 2025-02-19 抗ヒトｐ４０タンパク質ドメイン抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025024929A Pending JP2025081517A (ja) 2019-07-30 2025-02-19 抗ヒトｐ４０タンパク質ドメイン抗体及びその使用

Country Status (13)

Country Link
US (1) US12595300B2 (https=)
EP (1) EP4008727A4 (https=)
JP (2) JP7638955B2 (https=)
KR (1) KR20220038775A (https=)
CN (1) CN112079922B (https=)
AU (1) AU2020320910A1 (https=)
BR (1) BR112022001632A2 (https=)
CA (1) CA3145909A1 (https=)
IL (1) IL290167A (https=)
MX (1) MX2022001305A (https=)
PH (1) PH12022550223A1 (https=)
WO (1) WO2021018114A1 (https=)
ZA (1) ZA202202380B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022001632A2 (pt) 2019-07-30 2022-04-19 Akeso Biopharma Inc Anticorpos, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, conjugado de anticorpo, proteína de fusão, kit, usos do anticorpo, composição farmacêutica, métodos in vivo ou in vitro, para preparar o anticorpo e para prevenção, tratamento, tratamento adjuvante e/ou de diagnóstico de doenças autoimunes
CN118620077B (zh) * 2024-08-13 2024-11-12 苏州百道医疗科技有限公司 一种抗p40重组兔单克隆抗体及其应用
WO2026062296A1 (en) * 2024-09-23 2026-03-26 Ose Immunotherapeutics Therapy by antagonizing il-7 or cd127, and il-12, il-23, il-12r or il-23r

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004527212A (ja) 2000-08-07 2004-09-09 セントカー・インコーポレーテツド 抗ｉｌ−１２抗体、組成物、方法および使用
CN103275222A (zh) 2013-05-15 2013-09-04 中山康方生物医药有限公司 一种阻断白介素12 p40功能的单克隆抗体及其编码基因和应用
JP2014506132A (ja) 2011-01-07 2014-03-13 アッヴィ・インコーポレイテッド 抗ｉｌ−１２／ｉｌ−２３抗体およびその使用
WO2019110691A1 (en) 2017-12-06 2019-06-13 Iontas Limited Selecting for developability of polypeptide drugs in eukaryotic cell display systems

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
CN103145842A (zh) * 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
WO2009114040A2 (en) * 2007-09-28 2009-09-17 Centocor Ortho Biotech Inc. Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses
KR20160116056A (ko) * 2008-08-14 2016-10-06 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 항-ｉｌ-12/ｉｌ-23 항체
CN103813804A (zh) * 2010-10-06 2014-05-21 Abbvie公司 用于治疗银屑病的方法
PT2692865E (pt) * 2012-07-30 2015-02-06 Nbe Therapeutics Llc Identificação mediada por transposição de proteínas funcionais ou de ligação específicas
BR112015013431A2 (pt) * 2012-12-12 2017-11-14 Vasculox Inc anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos
CN109293777A (zh) * 2015-11-13 2019-02-01 叶才果 双功能抗体及其用途
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
BR112022001632A2 (pt) 2019-07-30 2022-04-19 Akeso Biopharma Inc Anticorpos, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, conjugado de anticorpo, proteína de fusão, kit, usos do anticorpo, composição farmacêutica, métodos in vivo ou in vitro, para preparar o anticorpo e para prevenção, tratamento, tratamento adjuvante e/ou de diagnóstico de doenças autoimunes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004527212A (ja) 2000-08-07 2004-09-09 セントカー・インコーポレーテツド 抗ｉｌ−１２抗体、組成物、方法および使用
JP2014506132A (ja) 2011-01-07 2014-03-13 アッヴィ・インコーポレイテッド 抗ｉｌ−１２／ｉｌ−２３抗体およびその使用
CN103275222A (zh) 2013-05-15 2013-09-04 中山康方生物医药有限公司 一种阻断白介素12 p40功能的单克隆抗体及其编码基因和应用
WO2019110691A1 (en) 2017-12-06 2019-06-13 Iontas Limited Selecting for developability of polypeptide drugs in eukaryotic cell display systems

Also Published As

Publication number Publication date
ZA202202380B (en) 2025-06-25
PH12022550223A1 (en) 2022-12-19
WO2021018114A1 (zh) 2021-02-04
MX2022001305A (es) 2022-05-06
JP2022544050A (ja) 2022-10-17
BR112022001632A2 (pt) 2022-04-19
IL290167A (en) 2022-03-01
CN112079922A (zh) 2020-12-15
CN112079922B (zh) 2022-08-12
EP4008727A4 (en) 2024-01-17
JP2025081517A (ja) 2025-05-27
AU2020320910A1 (en) 2022-03-10
CA3145909A1 (en) 2021-02-04
KR20220038775A (ko) 2022-03-29
US20220298235A1 (en) 2022-09-22
EP4008727A1 (en) 2022-06-08
US12595300B2 (en) 2026-04-07

Similar Documents

Publication Publication Date Title
US20250179199A1 (en) Antibodies to canine interleukin-4 receptor alpha
EP2187964B1 (en) High affinity human antibodies to human nerve growth factor
AU2009311496B9 (en) High affinity human antibodies to human IL-4 receptor
CN103946238B (zh) 抗ox40抗体及使用其的方法
JP2023126929A (ja) ヒトｉｌ４ｒａに対する抗体及びその使用
JP2025081517A (ja) 抗ヒトｐ４０タンパク質ドメイン抗体及びその使用
CN106554417A (zh) 抗ox40抗体和使用其的方法
AU2014216019B2 (en) High affinity human antibodies to Human IL-4 receptor
EA048249B1 (ru) Античеловеческие антитела к домену белка р40 и их применение
JP6529602B2 (ja) 抗ｃｄ２０／抗ｂａｆｆ二重特異性抗体
HK1144379B (en) High affinity human antibodies to human nerve growth factor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240925

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250219

R150 Certificate of patent or registration of utility model

Ref document number: 7638955

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150